One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study
- 1 August 1999
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 13 (8) , 1079-1084
- https://doi.org/10.1046/j.1365-2036.1999.00580.x
Abstract
Background : We have previously shown that ranitidine bismuth citrate (RBC)‐based triple therapy is comparable to proton pump inhibitor‐based triple therapy in eradicating Helicobacter pylori infection. Aim : To test the efficacy of different combinations of antimicrobials with RBC in the treatment of H. pylori infection. Methods : Dyspeptic patients with H. pylori infection were prospectively randomized to receive one of the following regimens: (i) RBC 400 mg, amoxycillin 1 g, clarithromycin 500 mg [RAC]; (ii) RBC 400 mg, metronidazole 400 mg, clarithromycin 500 mg [RMC]; (iii) RBC 400 mg, metronidazole 400 mg, tetracycline 1 g [RMT] (all given twice daily for 1 week); or (iv) RBC 400 mg plus clarithromycin 500 mg twice daily for 2 weeks [RC‐2]. Endoscopy (rapid urease test and culture) and 13C‐urea breath test (UBT) were performed before randomization. Four weeks after finishing medication, the 13C‐UBT was repeated in all cases and endoscopy was offered to patients with peptic ulcers. Results : Four hundred patients were randomized but in two (one in the RAC group and one in the RMC group) H. pylori infection was not confirmed. Successful eradication of H. pylori (intention‐to‐treat analysis and 95% CI) of RAC (86% [79–93%]), RMC (90% [84–96%]), RMT (79% [71–87%]) and RC‐2 (82% [75–90%]) were comparable, with a trend favouring clarithromycin‐containing triple therapy regimens. Among 276 isolates tested for antibiotic sensitivity, primary resistance to metronidazole, clarithromycin and amoxycillin was found in 56%, 2% and 0.4%, respectively. When given RMC or RMT, patients infected by metronidazole‐resistant H. pylori had success in eradicating H. pylori similar to patients infected by metronidazole‐sensitive H. pylori. Conclusion : One‐week RBC triple therapy is effective in curing H. pylori infection.Keywords
This publication has 16 references indexed in Scilit:
- Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics, 1999
- Triple regimens using lansoprazole or ranitidine bismuth citrate for Helicobacter pylori eradicationAlimentary Pharmacology & Therapeutics, 1998
- Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infectionAlimentary Pharmacology & Therapeutics, 1998
- One‐week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori‐related duodenal ulcerAlimentary Pharmacology & Therapeutics, 1998
- Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.Gut, 1997
- The Role of Ranitidine Bismuth Citrate in Significantly Reducing the Emergence of Helicobacter pylori Strains Resistant to AntibioticsHelicobacter, 1997
- Eradication of Helicobacter pylori Using One‐week Triple Therapies Combining Omeprazole with Two Antimicrobials: The MACH I StudyHelicobacter, 1996
- Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group [see comments]Alimentary Pharmacology & Therapeutics, 1996
- An Increase in Helicobacter pylori Strains Resistant to Metronidazole: A Five‐Year StudyHelicobacter, 1996
- Antimicrobial susceptibility testing of Helicobacter pylori comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazoleDiagnostic Microbiology and Infectious Disease, 1996